Pharmaceutical Investing DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
Pharmaceutical Investing DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market
Pharmaceutical Investing DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
Life Science Investing DelMar Pharmaceuticals, Inc. – "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson"
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy
